Universal White Blood Cell Reduction in Europe: Has Transmission of Variant Creutzfeldt-Jakob Disease Been Prevented?

Transfusion Medicine Reviews

Volumn 25, Issue 2, 2011, Pages 133-144

  Vamvakas, Eleftherios C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; PRION PROTEIN;

ARTICLE; BLOOD FILTRATION; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; BOVINE SPONGIFORM ENCEPHALOPATHY AGENT; DIETARY INTAKE; DISEASE TRANSMISSION; EPIDEMIC; ERYTHROCYTE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFECTION RISK; LEUKOCYTE; NONHUMAN; PLASMA; PREVALENCE; SCRAPIE; SHEEP; UNITED KINGDOM; VARIANT CREUTZFELDT JAKOB DISEASE;

ANIMALS; BLOOD TRANSFUSION; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; EUROPE; GREAT BRITAIN; HUMANS; LEUKOCYTES; MICE; PLASMA; PRIONS; SHEEP;

EID: 79952694266     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2010.11.005     Document Type: Article

References (55)

1. Mabbott N., Turner M. Prion and the blood immune systems. Haematologica 2005, 90:542-548.
2. Vamvakas E.C., Blajchman M.A. Universal white-cell reduction: The case for and against. Transfusion 2001, 41:691-712.
3. Dzik S., AuBuchon J., Jeffries L., et al. Leukocyte reduction of blood components: Public policy and new technology. Transf Med Rev 2000, 14:34-52.
4. Blajchman M.A. The clinical benefits of leukoreduction of blood products. J Trauma 2006, 60:S83-S90.
5. Blajchman M.A. Allogeneic blood transfusions, immunomodulation and postoperative bacterial infection. Do we have the answers yet?. Transfusion 1997, 37:121-125.
6. Immunomodulatory Effects of Blood Transfusion 1999, AABB Press, Bethesda, MD. E.C. Vamvakas, M.A. Blajchman (Eds.).
7. Vamvakas E., Blajchman M.A. Transfusion-related immunomodulation: An update. Blood Rev 2007, 21:327-348.
8. Foster K.R., Vecchia P., Repacholi M.H. Risk management: Science and the precautionary principle. Science 2000, 288:978-981.
9. Wilson K., Wilson M., Hébert P.C., et al. The application of the precautionary principle to the blood system: The Canadian blood system's vCJD donor deferral policy. Transf Med Rev 2003, 17:89-94.
10. Wilson K., Ricketts M.N. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease. Transfusion 2004, 47:1475-1478.
11. University of Edinburgh UK Creutzfeldt-Jakob Disease Surveillance Unit Accessed December 24, 2010. http://www.cjd.ed.ac.uk.
12. Ghani A.C., Donnelly C.A., Ferguson N.M., et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003, 3:4.
13. Hilton D.A., Ghani A.C., Conyers L., et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004, 203:733-739.
14. Clark P., Ghani A.C. Projections of future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2005, 2:19-31.
15. Wadsworth J.D., Asante E.A., Desbruslais M., et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004, 306:1793-1796.
16. Collinge J., Whitfield J., Mckintosh E., et al. Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet 2006, 367:2068-2074.
17. Clarke P., Will R.G., Ghani A.C. Is there a potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?. J R Soc Interface 2007, 4:675-684.
18. Bishop M.T., Hart P., Aitchison L., et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006, 5:393-398.
19. Ironside J.W., Bishop M.T., Connolly K., et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006, 332:1186-1188.
20. Mead S., Joiner S., Desbruslais M., et al. Creutzfeldt-Jakob disease, prion-protein gene codon 129 VV, and a novel PrPSc type in a young British woman. Arch Neurol 2007, 64:1780-1784.
21. Pincock S. Patient's death from vCJD may be linked to blood transfusion. Committee to discuss need for further precautions to prevent possible vCJD transmission through blood. Lancet 2004, 363:43.
22. Llewelyn C.A., Hewitt P.E., Knight R.S., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363:417-421.
23. Hewitt P.E., Llewelyn C.A., Mackenzie J., et al. Creutzfeldt-Jakob disease and blood transfusion: Results of the UK Transfusion Epidemiology Review Study. Vox Sang 2006, 91:221-230.
24. Health Protection Agency Fourth case of transfusion-associated variant CJD. Health Prot Rep 2007, 1.
25. Lefrère J.J., Hewitt P. From cows to sensible blood transfusion: The risk of prion transmission from labile blood components in the United Kingdom and France. Transfusion 2009, 49:797-812.
26. Cholan G., Llewelyn C., Mackenzie J., et al. Variant Creutzfeldt-Jacob disease in a transfusion recipient: Coincidence or cause?. Transfusion 2010, 50:1003-1006.
27. Irena M., Farguhar C.F., Outram G.W., et al. Resistance of neonatal mice to scrapie is associated with inefficient infection of the premature spleen. J Virol 2006, 80:474-482.
28. Lee C.A., Ironside J.W., Bell J.E., et al. Retrospective neuropathological review of prion disease in UK hemophilia patients. Thromb Haemost 1998, 80:909-911.
29. Health Protection Agency Asymptomatic vCJD abnormal prion protein in a hemophilia patient Available at:. http://www.hpa.org.uk/webw/HPAweb&HPAwebstandard/HPAweb_C/1195733818681?p=1225960597236.
30. Houston F., McCutcheon S., Goldmann W., et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008, 112:4739-4745.
31. Turner M.L., Ludlam C.A. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009, 144:14-23.
32. SEAC Minutes of the 104th meeting of the Spongiform Encephalopathy Advisory Committee, London, UK, March 5, 2010 Available at:. http://www.seac.gov.uk/summaries/seac104-summary.pdf.
33. Brown P., Rohwer R.G., Dunstan B.C., et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissiform spongiform encephalopathy. Transfusion 1998, 38:810-816.
34. Cervenakova L., Yakovleva O., McKenzie C., et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003, 43:1687-1694.
35. Gregori L., Grugel P.V., Lathorp J.T., et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006, 368:2226-2230.
36. Gregori L., McCombie N., Palmer D., et al. Effectiveness of leukoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004, 364:529-531.
37. Gregori L., Lambert B.C., Gurgel P.V., et al. Reduction of transmissible spongiform encephalopathy infectivity from human red cells with prion protein affinity ligands. Transfusion 2006, 46:1152-1161.
38. Saunders C., Herbert P., Rowe M., et al. In-vitro evaluation of the Pall Leukotrap affinity prion reduction filter as a secondary device following primary leukoreduction. Vox Sang 2007, 89:220-228.
39. Sowenimo-Coker S.O., Kascsak R., Kim A., et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukocyte filtration filer. Transfusion 2005, 45:1839-1844.
40. Sowenimo-Coker S.O., Pesci S., Andrade F., et al. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang 2006, 90:265-275.
41. Wiltshire M., Thomas S., Scott J., et al. Prion reduction of red blood cells: Impact on component quality. Transfusion 2010, 50:970-979.
42. Cahill M.R., Murphy T., Khan M., et al. Phase I/II safety study of transfusion of prion-filtered red-cell concentrates in transfusion-dependent patients. Vox Sang 2010, 99:174-176.
43. Dodd R.Y. Prions and precautions: be careful for what you ask. Transfusion 2010, 50:956-958.
44. Eglin R.P., Murphy W.G. Beyond leukodepletion: Removing infectious prions by filtration. Transfusion 2005, 45:1836-1838.
45. Brown P. Blood infectivity, processing, and screening tests in transmissible spongiform encephalopathy. Vox Sang 2005, 89:63-70.
46. Blanco A.R., McCutcheon S., de Wolf C., et al. The effect of leukodepletion on transmission of BSE by transfusion of sheep blood components. Prion 2009-Transmissible Spongiform Encephalopathies Meeting, September 23-25 2009, Thessaloniki-Chalkidiki, Greece.
47. Benson A.B., Moss M., Silliman C.C. Transfusion-related acute lung injury (TRALI): A clinical review with emphasis on the critically ill. Br J Haematol 2009, 147:431-443.
48. Holada K., Vostal J.G., Theisen P.W., et al. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002, 76:4649-4650.
49. SEAC Position statement: Position statement on TSE infectivity in blood 2006, Spongiform Encephalopathy Advisory Committee, London, UK, [Updated 2006 August 21] Available at:. http://www.seac.gov.uk/statements/statement0806.htm.
50. Barclay G.R., Hope J., Brickett C.R., et al. Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry. Br J Haematol 1999, 107:804-814.
51. Sivakumaran M. Infectivity of buffy coat in variant CJD. Transfusion 2000, 40:754-755.
52. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009, 23:124-133.
53. MacLennan S., Barbara J.A. Risks and side-effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006, 19:169-189.
54. Farrugia A., Ironside J.W., Giagrande P. Variant Creutzfeldt-Jakob disease transmission by plasma products: Assessing and communicating risk in an era of scientific uncertainty. Vox Sang 2005, 89:186-192.
55. Dietz K., Raddatz G., Wallis J., et al. Blood transfusion and spread of variant Creutzfeldt-Jacob disease. Emerg Infect Dis 2007, 13:89-96.